Grantham Mayo Van Otterloo & Co. LLC Acquires 481 Shares of Amgen Inc. $AMGN

Grantham Mayo Van Otterloo & Co. LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 12.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,245 shares of the medical research company’s stock after buying an additional 481 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Amgen were worth $1,185,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new stake in shares of Amgen in the first quarter worth $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen during the 2nd quarter worth about $27,000. CBIZ Investment Advisory Services LLC grew its position in shares of Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after buying an additional 85 shares during the last quarter. Evelyn Partners Investment Management LLP acquired a new stake in shares of Amgen in the second quarter valued at about $32,000. Finally, Activest Wealth Management increased its stake in shares of Amgen by 3,433.3% in the first quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock valued at $33,000 after buying an additional 103 shares during the period. 76.50% of the stock is owned by institutional investors.

Amgen Trading Down 2.3%

NASDAQ:AMGN opened at $337.49 on Tuesday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $345.84. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The stock has a market capitalization of $181.73 billion, a price-to-earnings ratio of 27.60, a PEG ratio of 2.61 and a beta of 0.45. The firm has a fifty day simple moving average of $308.54 and a two-hundred day simple moving average of $295.60.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. The company had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, November 21st. This represents a $9.52 annualized dividend and a dividend yield of 2.8%. Amgen’s payout ratio is currently 73.57%.

Wall Street Analyst Weigh In

Several brokerages recently commented on AMGN. HSBC upped their target price on Amgen from $343.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Scotiabank assumed coverage on shares of Amgen in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $333.74.

Insider Transactions at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 10,908 shares of company stock valued at $3,674,966 over the last ninety days. 0.76% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.